scholarly journals Correction for: YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression

Aging ◽  
2021 ◽  
pp. 23871-23871
Author(s):  
Pol Andrés‐Benito ◽  
Raúl Domínguez ◽  
Maria J. Colomina ◽  
Franc Llorens ◽  
Mònica Povedano ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Cerebrospinal Fluid ◽  
Disease Progression ◽  
Sporadic Amyotrophic Lateral Sclerosis ◽  
Cerebrospinal Fluid Levels ◽  
Prognosis Marker ◽  
Fluid Levels ◽  
Lateral Sclerosis

scholarly journals YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression

Aging ◽  
2018 ◽  
Vol 10 (9) ◽  
pp. 2367-2382 ◽  
Author(s):  
Pol Andrés-Benito ◽  
Raúl Domínguez ◽  
Maria J. Colomina ◽  
Franc Llorens ◽  
Mònica Povedano ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Cerebrospinal Fluid ◽  
Disease Progression ◽  
Sporadic Amyotrophic Lateral Sclerosis ◽  
Cerebrospinal Fluid Levels ◽  
Prognosis Marker ◽  
Fluid Levels ◽  
Lateral Sclerosis

Cerebrospinal fluid levels of alpha-tocopherol in amyotrophic lateral sclerosis

1998 ◽  
Vol 105 (6-7) ◽  
pp. 703-708 ◽  
Author(s):  
F. de Bustos ◽  
F. J. Jiménez-Jiménez ◽  
J. A. Molina ◽  
J. Esteban ◽  
A. Guerrero-Sola ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Cerebrospinal Fluid ◽  
Alpha Tocopherol ◽  
Cerebrospinal Fluid Levels ◽  
Fluid Levels ◽  
Lateral Sclerosis

Cerebrospinal fluid levels of chromogranin A and phosphorylated neurofilament heavy chain are elevated in amyotrophic lateral sclerosis

2017 ◽  
Vol 136 (4) ◽  
pp. 360-364 ◽  
Author(s):  
M. Kaiserova ◽  
Z. Grambalova ◽  
P. Otruba ◽  
D. Stejskal ◽  
H. Prikrylova Vranova ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Cerebrospinal Fluid ◽  
Heavy Chain ◽  
Chromogranin A ◽  
Cerebrospinal Fluid Levels ◽  
Fluid Levels ◽  
Lateral Sclerosis

Increased cerebrospinal fluid levels of substance P in patients with amyotrophic lateral sclerosis

1999 ◽  
Vol 106 (9-10) ◽  
pp. 943-948 ◽  
Author(s):  
T. Matsuishi ◽  
S. Nagamitsu ◽  
H. Shoji ◽  
M. Itoh ◽  
S. Takashima ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Cerebrospinal Fluid ◽  
Substance P ◽  
Cerebrospinal Fluid Levels ◽  
Fluid Levels ◽  
Lateral Sclerosis

Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis?

2019 ◽  
pp. jnnp-2018-319586 ◽  
Author(s):  
Benjamin Gille ◽  
Maxim De Schaepdryver ◽  
Lieselot Dedeene ◽  
Janne Goossens ◽  
Kristl G Claeys ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Cerebrospinal Fluid ◽  
Disease Progression ◽  
Inflammatory Markers ◽  
Cox Regression ◽  
Characteristic Curve ◽  
Progression Rate ◽  
Cox Regression Analysis ◽  
Lateral Sclerosis ◽  
Discriminatory Performance

ObjectiveInflammation is a key pathological hallmark in amyotrophic lateral sclerosis (ALS), which seems to be linked to the disease progression. It is not clear what the added diagnostic and prognostic value are of inflammatory markers in the cerebrospinal fluid (CSF) of patients with ALS.MethodsChitotriosidase-1 (CHIT1), chitinase-3-like protein 1 (YKL-40) and monocyte chemoattractant protein-1 (MCP-1) were measured in CSF and serum of patients with ALS (n=105), disease controls (n=102) and patients with a disease mimicking ALS (n=16). The discriminatory performance was evaluated by means of a receiver operating characteristic curve analysis. CSF and serum levels were correlated with several clinical parameters. A multivariate Cox regression analysis, including eight other established prognostic markers, was used to evaluate survival in ALS.ResultsIn CSF, CHIT1, YKL-40 and MCP-1 showed a weak discriminatory performance between ALS and ALS mimics (area under the curve: 0.79, p<0.0001; 0.72, p=0.001; 0.75, p=0.001, respectively). CHIT1 and YKL-40 correlated with the disease progression rate (ρ=0.28, p=0.009; ρ=0.34, p=0.002, respectively). CHIT1 levels were elevated in patients with a higher number of regions displaying motor neuron degeneration (one vs three regions: 4248 vs 13 518 pg/mL, p = 0.0075). In CSF, YKL-40 and MCP-1 were independently associated with survival (HR: 29.7, p=0.0003; 6.14, p=0.001, respectively).ConclusionsOur findings show that inflammation in patients with ALS reflects the disease progression as an independent predictor of survival. Our data encourage the use of inflammatory markers in patient stratification and as surrogate markers of therapy response in clinical trials.

Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis

2017 ◽  
Vol 89 (4) ◽  
pp. 367-373 ◽  
Author(s):  
Maxim De Schaepdryver ◽  
Andreas Jeromin ◽  
Benjamin Gille ◽  
Kristl G Claeys ◽  
Victor Herbst ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Cerebrospinal Fluid ◽  
Motor Neuron ◽  
Disease Progression ◽  
Roc Curves ◽  
Symptom Duration ◽  
Progression Rate ◽  
Alternative Source ◽  
Disease Progression Rate ◽  
Lateral Sclerosis

ObjectivePhosphorylated neurofilament heavy chain (pNfH) levels are elevated in cerebrospinal fluid (CSF) of patients with amyotrophic lateral sclerosis (ALS). Instead of CSF, we explored blood as an alternative source to measure pNfH in patients with ALS.MethodsIn this single centre retrospective study, 85 patients with ALS, 215 disease controls (DC) and 31 ALS mimics were included. Individual serum pNfH concentrations were correlated with concentrations in CSF and with several clinical parameters. The performance characteristics of pNfH in CSF and serum of patients with ALS and controls were calculated and compared using receiver operating characteristic (ROC) curves.ResultsCSF and serum pNfH concentrations in patients with ALS correlated well (r=0.652, p<0.0001) and were significantly increased compared with DC (p<0.0001) and ALS mimics (p<0.0001). CSF pNfH outperformed serum pNfH in discriminating patients with ALS from DC and ALS mimics (difference between area under the ROC curves: p=0.0001 and p=0.0005; respectively). Serum pNfH correlated inversely with symptom duration (r=−0.315, p=0.0033). CSF and serum pNfH were lower when the disease progression rate was slower (r=0.279, p<0.01 and r=0.289, p<0.01; respectively). Unlike CSF, serum pNfH did not correlate with the burden of clinical and electromyographic motor neuron dysfunction.ConclusionsCSF and serum pNfH concentrations are elevated in patients with ALS and correlate with the disease progression rate. Moreover, CSF pNfH correlates with the burden of motor neuron dysfunction. Our findings encourage further pursuit of CSF and serum pNfH concentrations in the diagnostic pathway of patients suspected to have ALS.

Sign in / Sign up

Export Citation Format

Share Document